Community-acquired pneumonia, including multidrug-resistant strains of S. pneumoniae. Nosocomial pneumonia, chronic bronchitis (acute bacterial exacerbation), acute bacterial sinusitis, prostatitis, UTI, acute pyelonephritis, skin or skin structure infection. Reduce incidence or disease progression of inhalational anthrax (post-exposure).
Dosage/Direction for Use
250-500 mg. Severe or complicated infections 750 mg 24-hrly for 7-14 days. Renal impairment CrCl <50 mL/min Dosage adjustment is required.
Hypersensitivity to levofloxacin or other quinolones.
Increased risk of tendon inflammation &/or rupture w/ concurrent corticosteroids, organ transplant recipients, patient >60 yr. CNS effects may occur. Rarely, increased potential for seizures w/ concomitant NSAID therapy. Avoid excessive sunlight. Exacerbation of myasthenia gravis w/ quinolones. Childn <18 yr is only recommended for systemic use for prevention of inhalational anthrax.
Nausea, diarrhea, constipation, headache, insomnia, dizziness, inj site reaction.